Zimbabwe has declined a major US healthcare agreement valued at 367 million US dollars (£272m) over five years over Washington's demand for sensitive data.
This rejection came to light following a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "skewed".
A government spokesperson later stated that the US was seeking health data for scientific study and commercial purposes but was unwilling to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated over $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged continued negotiations to secure a agreement suitable to all parties so the country's critical HIV treatment initiative can proceed.
Wider Context
This rejection comes after a similar case in neighbouring Kenya, where a high court blocked a similar health funding agreement following legal challenges were raised about the security of citizens' health data.
After returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump argued its expenditure was "wasteful" and his government was seeking direct bilateral deals to boost openness and responsibility.
Based on statements, Sixteen African countries have so far agreed to similar health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered immense advantages for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information indefinitely, with no equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that might result from that shared data," his statement read.
"In essence, our country would supply the basic resources for scientific discovery without any certainty that the final treatments would be accessible to our citizens should a future pandemic arise."
National Interest and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining structures already set up via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to deal with potential pandemics.
"This mechanism is intended to ensure that when a nation provides its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," he added.
"We welcome further discussions with our American counterparts on how subsequent collaboration might be arranged in a manner that honours the sovereignty and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but urged that negotiations need to persist since much of the country's Aids initiatives relied on foreign aid.
"In cases where technical issues arise, such as those relating to data governance or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," it said.
The situation highlights the ongoing debate between accepting vital foreign assistance and protecting a country's data in an increasingly data-driven world.